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Abstract
Background: Traditional herbal medicines are commonly used in sub-Saharan Africa and some herbs are known to be
hepatotoxic. However little is known about the effect of herbal medicines on liver disease in sub-Saharan Africa.
Methods: 500 HIV-infected participants in a rural HIV care program in Rakai, Uganda, were frequency matched to 500 HIV-
uninfected participants. Participants were asked about traditional herbal medicine use and assessed for other potential risk
factors for liver disease. All participants underwent transient elastography (FibroScanH) to quantify liver fibrosis. The
association between herb use and significant liver fibrosis was measured with adjusted prevalence risk ratios (adjPRR) and
95% confidence intervals (CI) using modified Poisson multivariable logistic regression.
Results: 19 unique herbs from 13 plant families were used by 42/1000 of all participants, including 9/500 HIV-infected
participants. The three most-used plant families were Asteraceae, Fabaceae, and Lamiaceae. Among all participants, use of
any herb (adjPRR=2.2, 95% CI 1.3–3.5, p=0.002), herbs from the Asteraceae family (adjPRR=5.0, 95% CI 2.9–8.7, p,0.001),
and herbs from the Lamiaceae family (adjPRR=3.4, 95% CI 1.2–9.2, p=0.017) were associated with significant liver fibrosis.
Among HIV infected participants, use of any herb (adjPRR=2.3, 95% CI 1.0–5.0, p=0.044) and use of herbs from the
Asteraceae family (adjPRR=5.0, 95% CI 1.7–14.7, p=0.004) were associated with increased liver fibrosis.
Conclusions: Traditional herbal medicine use was independently associated with a substantial increase in significant liver
fibrosis in both HIV-infected and HIV-uninfected study participants. Pharmacokinetic and prospective clinical studies are
needed to inform herb safety recommendations in sub-Saharan Africa. Counseling about herb use should be part of routine
health counseling and counseling of HIV-infected persons in Uganda.
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Traditional herbal medicines are commonly used for HIV/
AIDS and other health conditions in Uganda and sub-Saharan
Africa, often in parallel with programs that provide antiretroviral
therapy (ART). In the 1990’s an estimated 80% of Ugandans
living in rural villages used traditional healers for primary health
care [1]. A study of 137 HIV-infected Ugandans receiving ART
found that 60% used herbs concurrently with ART [2].
In Uganda traditional herbal medicines are usually boiled
extracts of herbs taken orally [3]. Some potentially hepatotoxic
traditional herbal medicines used in Uganda and sub-Saharan
Africa include Hoodia gordoni [4], kava [5], Phytolacca dioica [6], and
herbs from the Asteraceae family [7]. Little is known about the
hepatotoxicity of other commonly used herbs or the contribution
of herbs to the burden of liver fibrosis and hepatocellular
carcinoma in sub- Saharan Africa, including when used concom-
itantly with ART. Data on the specific types of herbs taken by
HIV-infected persons in Uganda is limited, as is information about
their components, side effects, toxicities, and ART interactions [8].
In Rakai, Uganda, liver toxicity associated with herbal medicine
may be of particular concern given the high prevalence of
significant liver disease (17%) among HIV-infected persons in
Rakai recently identified by transient elastography (FibroScanH,
Echosense, Paris, France) [9]. In the aforementioned study,
reported herbal medicine use was associated with a two-fold
increased risk of significant liver disease, defined as a transient
elastography score equivalent to METAVIR liver fibrosis stage 2
(portal fibrosis with few septa) or greater [9]. The study presented
here follows up on this prior investigation with an in-depth analysis
of the herbs used by study participants and their relation to liver
fibrosis.
Methods
This cross-sectional study enrolled 500 HIV-infected partici-
pants receiving care at five HIV care clinics within the Rakai
Health Sciences Program (RHSP) HIV Care Program. 500 HIV-
uninfected participants from the Rakai Community Cohort Study
(RCCS) were frequency- matched to these participants by age,
gender, and community. Begun in 1994 in one of Uganda’s
hardest-hit regions by the HIV epidemic, the RCCS conducts
annual surveys in a population of 10,000–15,000 people aged 15–
49 years, and is described in detail elsewhere [10]. Participants
underwent a detailed liver-disease focused risk factor questionnaire
which included an assessment of herbal drug use, venous blood
collection, and transient elastography (FibroScanH, Echosense,
Paris, France) to quantify liver fibrosis.
Ethics Statement
Written informed consent was obtained from all participants.
Institutional Review Boards of theNational Institute of Allergy and
Infectious Diseases, the Johns Hopkins Medical Institutions, the
Scientific and Ethics Committee of the Uganda Virus Research
Institute, and the Uganda National Council for Science and
Technology approved this study. The study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki, and is
registered on clinicaltrials.gov (#NCT00782158).
Herb Use Assessment
Participants were asked about any current herb use and then to
name the two herbs they used most often. Scientific names were
assigned to local herb names in consultation with local traditional
medicine practitioners and a member of Makerere University
Botany Department (CKB). The Makerere University Herbarium
database was also used to validate herb identities. Some
participants reported non-plant substances such as clay and
spiritual charms as herb use. Participants reporting use of non-
plant based entities were reclassified as non-herb users in this
analysis.
Laboratory Assays
HIV-1 serology was determined by two HIV-1 enzyme
immuno-assays: Vironostika HIV-1 (OrganonTeknika, Charlotte,
North Carolina, USA) and Cambridge Biotech (Worcester,
Massachusetts, USA). Participants with discrepant HIV-1 enzyme
immune assay results were tested with western blot (HIV-1
Western Blot; Bio-Merieux-Vitek, St. Louis, Missouri, USA). For
HIV-infected participants, current CD4 count (within 12 months)
and CD4 count nadir were abstracted from the RHSP HIV Care
Program database. CD4 counts were measured by FACSCalibur
flow cytometer (software version 1.4, Becton Dickinson, San Jose,
California, USA). Hepatitis B virus surface antigen (HBsAg) was
determined using ELISA (ETI-MAK-2 Plus, Diasorin, Vercelli,
Italy). Alanine aminotransferase (ALT) was tested using standard
methods (COBAS CII; Roche, Basel, Switzerland), and hepato-
toxicity was defined by ALT elevations and classified according to
AIDS Clinical Trial Group criteria [11]. The upper limit of
normal for ALT was defined as 19 IU/L in women and 39 IU/L
in men [12,13].
Transient Elastography
Transient elastography or FibroScanH is a novel, validated,
noninvasive technology for the evaluation of fibrosis in chronic
liver disease [14]. A FibroScanH is approximately the size of an
ultrasound unit. A probe placed over a patient’s abdomen
produces vibration and the speed of the responding elastic wave
is detected by ultrasound. The propagation of these waves through
the liver is directly correlated to the degree of liver stiffness. The
results are instantaneously received as a single, quantitative
parameter of liver stiffness measurement (LSM, reported in kPa).
Each transient elastography scan takes ten liver stiffness measure-
ments in rapid succession over several seconds. The median of the
ten measurements is reported as the final liver stiffness measure-
ment. The procedure is non-invasive, painless, has no side effects,
and requires only a few minutes to perform. The device requires
minimal training and does not need to be performed by advanced
medical personnel.
In this study a conservative liver stiffness measurement cutoff of
$9.3 kPa, from a validation study in persons of predominantly
African descent, was used to define significant fibrosis equivalent
to METAVIR fibrosis stage 2 (portal fibrosis with few septa) or
greater [15]. Two study nurses at the Rakai Health Science
Program study site conducted all transient elastography scans after
receiving certification from the manufacturer. According to
manufacturer recommendations, scans with high variability—
defined as an interquartile range greater than 30% of the median
LSM value from an individual examination—were not considered
valid and were excluded from the analysis. Participants with
invalid scans on an initial attempt were repositioned and
rescanned up to 4 times to achieve a valid scan.
Statistics
Baseline demographic, behavioral and clinical characteristics
were compared by HIV status. Differences in continuous variables
were assessed using t-tests and Wilcoxon-Mann-Whitney tests.
Categorical variables were compared using Pearson’s chi squared
test.
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ratios may overestimate the magnitude of association between
variables if the outcome of interest is common, adjusted
prevalence risk ratios (adjPRR) with 95% confidence intervals
(95% CI) were estimated using modified Poisson regression [16].
The multivariable models adjusted for HIV, gender, occupation in
the fishing industry, chronic hepatitis B infection (positive hepatitis
B surface antigen), and drinking $1.25 liters per week of liquor, as
these risk factors were associated with liver disease in previous
analysis of this study population [9]. Age was included in all
models and nadir CD4 cell count and ART status were included in
models restricted to HIV- infected participants for reasons of
biologic plausibility. STATA version 11.0 (STATA Corp, College
Station, TX) was used for statistical analysis.
Results
Baseline Characteristics
The HIV-infected and uninfected groups each had 67% females
(see table 1). The median age of 38 years in the HIV-infected
group was close to the median age of 37 years in the HIV-
uninfected group (p=0.025). Only 2% of both HIV-infected and
uninfected participants were heavy liquor drinkers (p=0.65). The
prevalence of chronic HBV infection was similar in both groups,
5% in HIV-infected participants and 3% in HIV-uninfected
participants (p=0.010). 29% of HIV-infected participants and
17% of HIV-uninfected participants had any grade 1 or higher
hepatotoxicity by AIDS Clinical Trial Group (ACTG) criteria
(p,0.001). No participants demonstrated grade 4 hepatotoxicity.
At the time of enrolment HIV-infected participants had a
median CD4 count of 449 cells/mL (IQR 320–642) and 60% were
receiving ART with a median duration of 19 months (IQR 9–38).
Demographics of the HIV-infected group were also similar to
participants in the Rakai Health Sciences HIV Care Program, in
which 65% of participants are female, 64% are on ART, and the
median CD4 count is 480 cells/mL.
468/500 (94%) of HIV-infected participants and 494/500
(99%) of HIV-uninfected participants had valid elastography
scans. Those with valid scans were included in the assessment of
liver fibrosis and were included in the regression models.
Table 1. Baseline characteristics of study participants.
HIV-infected pts (n=500) HIV-uninfected pts (n=500)
n (% or IQR) n (% or IQR) p value
Characteristic
Median Age, years 38 (IQR 31–44) 37 (IQR 32–44) 0.025
Female 312 (67%) 333 (67%) 0.89
Heavy Liquor use (.1.25 L/week) 11 (2%) 9 (2%) 0.65
Lifetime occupational fishing 5 (1%) 1 (0.2%) 0.65
HBsAg positive 23 (5%) 14 (3%) 0.10
Valid TE scan 468 (94%) 494 (99%) ,0.001
Herb Use
Current herb use 8 (2%) 33 (7%) 0.0001
Known herbs 5 (0.9%) 16 (3%) 0.015
Unknown herbs 4 (0.9%) 17 (3%) 0.004
Asteraceae family 2 (0.4%) 6 (1%) 0.16
Fabaceae family 0 (0%) 6 (1%) 0.014
Lamiaceae family 1 (0.2%) 4 (0.8%) 0.18
ACTG Heptatotoxicty Criteria
Median ALT (U/L) 22 (IQR 16–31) 19 (IQR 15–25) ,0.001
Grade 0 (,1.256ULN) by ALT 354 (71%) 414 (83%)
Grade 1 (1.25–2.56ULN) by ALT 122 (24%) 77 (15%)
Grade 2 (2.6–56ULN) by ALT 19 (4%) 9 (2%)
Grade 3 (5.1–106ULN) by ALT 5 (1%) 0 (0%)
Grade 4 (.106ULN) by ALT 0 (0%) 0 (0%)
CD4 and ART Characteristics
Current CD4 count (cells/uL) 449 (IQR 320–642)
Nadir CD4 count (cells/uL) 214 (IQR 130–350)
Nadir CD4 count ,100 cells/uL 95 (19%)
On ART 302 (60%)
ART duration (months) 19 (IQR 9–38)
HIV (Human Immunodeficiency Virus), IQR (Interquartile Range), HBsAg (Hepatitis B Surface Antigen), ACTG (AIDS Clinical Trials Group), CD4 (Cluster of Differentiation 4
positive Helper T cells), ART (Antiretroviral Therapy).
doi:10.1371/journal.pone.0041737.t001
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42/1000 (4%) of all participants reported current use of
traditional herbal medicines, including 9/500 (2%) of HIV-
infected participants and 33/500 (7%) HIV-uninfected partici-
pants (table 1). 21/42 (50%) of participants could name at least
one herb they were taking. 4/46 (9%) of participants reporting
Table 2. Characteristics of participants reporting current herb use.
Using Herbs (n=42) Not Using Herbs (n=958)
Characteristic n (% or IQR) n (% or IQR) p value
Median Age, years 39 (32–44 IQR) 38 (31–44 IQR) 0.61
Female 27 (64%) 643 (67%) 0.15
Heavy Liquor use (.1.25 L/week) 3 (7%) 17 (2%) 0.015
Lifetime occupational fishing 1 (2%) 5 (0.5%) 0.13
HBsAg positive 2 (5%) 35 (4%) 0.73
HIV infected 9 (20%) 491 (50%) 0.0001
L (Liters), HBsAg (Hepatitis B Surface Antigen), HIV (Human Immunodeficiency Virus).
doi:10.1371/journal.pone.0041737.t002
Table 3. Characteristics of known herbs in the Asteraceae, Fabaceae, and Lamiaceae families.
Family (n
taking)
Scientific
Name
Local Names (n
taking)
English
Name
Taken in
Rakai for: Known Pharmacology Known Liver Toxicity and/or ART Interaction
Asteraceae (8) Vernonia
amygdalina
Mululuza (4) Bitter leaf Fever, fever
with jaundice
Contains alkaloids,
saponins, tannins,
flavonoids, steroid
glycosides, sesquiterpine
lactone [32]
Hepatotoxic at high doses (750 mg/kg) [24]. One herb from
the Veronia genus (V. lasiopus) was hepatotoxic in an in-
vitro rat precision cut liver slice model [33]. Many herbs in
the Asteraceae family contain pyrrolizidine alkaloids, which
are associated with veno-occlusive liver disease [17]
Vernonia genus Kiluluuza (2)
Microglossa
densiflora
Kafugankande,
Akafugankande (1)
Fever,
indigestion,
loose stools,
parasites
Microglossa family
contains clerodane
diterpenoids [34]
A similar herb from the Microglossa family (M. pyrifolia)w a s
hepatotoxic in an in-vitro rat precision cut liver slice model
[33]. Many herbs in the Asteraceae family contain
pyrrolizidine alkaloids, which are associated with veno-
occlusive liver disease [17]
Aspilia africana Makaayi (1) Wild
sunflower
Fever with
jaundice
Contains saponins,
tannins, terpenoids,
Sesquiterpenes,
monoterpenes [35,36]
No hepatoxicity in rat in vivo model [38]. Many herbs in the
Asteraceae family contain pyrrolizidine alkaloids, which are
associated with veno-occlusive liver disease [17]
Fabaceae (6) Pseudarthria
hookeri
Bikakala, Kikakala,
Omukakala,
Mukakala (4)
Fever, fever
with jaundice,
allergy, cough,
wounds
May have estrogenic
activity [37]
Many herbs in the Fabaceae family contain pyrrolizidine
alkaloids, which are associated with veno-occlusive liver
disease [17]
Indigofera
congesta
Namasumi (2) Indigo Fever with
jaundice,
antenatal
health
Indigofera family
members contain
flavonoids, saponins,
quinones, sterols/
triterpenes, tannins, gallic
acid, caffeic acid, rutin and
myricetin [38]
Many herbs in the Fabaceae family contain pyrrolizidine
alkaloids, which are associated with veno-occlusive liver
disease [17]
Lamiaceae (5*)Ocimum
gratissimum
Mujaaja,
Omujaaja (3)
African
basil
Epigastric
pain
Contains tannin
phlobaphenes, flavones,
flavonols, xanthones,
chalcones, aurones,
terpenes, flavononols,
leucoanthocyanidins,
catechins [39]
Herb from Ocimum genus (O. lamiifolium) was hepatotoxic
in an in-vitro rat precision cut liver slice model [33], Ocimum
gratissimum caused hepatoxicity in-vivo rabbit liver model
[25]
Hoslundia
opposita
Kamunye (3) To replace
blood,
postnatal
health,
vomiting
during fever
and jaundice
Contains sesquiterpenes
and sesquiterpene
alcohols [40]
*one patient took both Ocimum gratissimum and Hoslundia oopposita. mg (milligrams), kg (kilograms).
doi:10.1371/journal.pone.0041737.t003
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reported use of inert, non-plant substances including clay. Herb
users did not differ by age (p=0.61) or gender (p=0.15) from
those who did not report herb use (see table 2). Herb users were
not more likely to work in the fishing industry (p=0.13) or have
chronic hepatitis B infection (p=0.73). 7% of participants
reporting herb use drank liquor heavily ($1.25 L/week), com-
pared to 2% of participants who did not report herb use
(p=0.015). 19 unique herbs from 13 families were used, and are
characterized in tables 3 and 4. The most common families were
Asteraceae, Fabaceae, and Lamiaceae, which were used by eight,
six and five participants, respectively.
Herb Use and Liver Fibrosis
Among the 137/962 (14%) subjects with significant liver
fibrosis, 12/137 (9%) reported herb use. Of the 825/962 (86%)
subjects without significant liver fibrosis, 29/825 (4%) reported
current herb use (p=0.005). 56/494 (11%) of HIV-uninfected
participants had significant fibrosis, compared to 81/468 (17%) of
HIV-infected participants (p=0.008).
In multivariable analysis that adjusted for age, fishing occupa-
tion, HIV infection, positive HBsAg, gender, and heavy liquor use,
herb use was associated with two to five fold increases in significant
liver fibrosis (see table 5). Among all participants, use of any herb
(adjPRR=2.2, 95% CI 1.3–3.5, p=0.002), herbs from the
Asteraceae family (adjPRR=5.0, 95% CI 2.9–8.7, p,0.001),
and herbs from the Lamiaceae family (adjPRR=3.4, 95% CI 1.2–
Table 4. Characteristics of known herbs in remainder of plant families.
Family (n taking) Scientific Name Local Names (n taking) English Name Taken in Rakai for:
Known
Pharmacology
Known Liver
Toxicity and/or ART
Interaction
Anacardiaceae (2) Rhus vulgaris or Rhus
natalenis
Olukansokanso,
akakwansokwanso (1)
Antenatal health,
aphrodisiac,
gastrointestinal ulcers,
back pain
No published
information about
contents
Mangifera indica Mango Tree Bark (1) Mango tree bark Leaves contains
flavonoids [41], Peel
contains phenolic
compounds and
carotenoids [42]
Primulaceae (2) Maesa lanceolata Oluwongwa, Oluwongo (2) Neonatal jaundice Contains Saponins [43],
benzoquinone [44]
Euphorbiaceae (2) Sapium ellipticum Musasa, Omusiisa,
Musanvuma (2)
Jumping tree
seed
Hypertension, antenatal
health, sexually
transmitted infections,
epigastric pain
Contains phenols [45]
Amaryllidaceae (1) Allium sativum Garlic (1) Garlic — Contians diallyl
disulfide [46]
Induces CYP3A4 and
Pgp and should not be
taken with the
following
antiretrovirals: APV,
ATV, AZT, EFV, IDV,
LPV, NFV, NVP, SQV
[27]
Bignoniaceae (1) Spathodea
campanulata
Ekifabakazi (1) African tulip tree Dysmennorrhea,
antenatal health
Contains 3b-
acetoxyoleanolic acid,
siaresinolic acid,
oleanolic acid, others
[47]
Solanaceae (1) Solanum incanum Akatengotengo (1) Sodom apple Cough, chest pain Contains alkaloids,
saponins, solanine;
High concentrations
cause hemolysis of
erythrocytes [48]
Herbs containing
pyrrolizidine alkaloids
are associated with
veno-occlusive liver
disease [17].
Vitaceae (1) Cyphostemma
adenocaule
Kamombo (1) Peptic ulcers Contain carotenoids
(carotenes),
xanthophylls, Vitamin
C, Tocopherols, and
Tocotrienols [49]
Myrtaceae (1) Callistemon citrinus Bottlebrush (1) Bottlebrush tree Rhino-sinusitis Contains 1,8-cineole,
apha-pinene [50]
Kagulukandayi,
Katangulucumu (1)
Epilepsy
Kakubamusolo (1)
APV (amprenavir), ATV (atazanavir), AZT (zidovudine), EFV (efavirenz), IDV indinavir), LPV (lopinavir), NFV (nelfinavir), NVP (nevirapine), SQV (saquinavir).
doi:10.1371/journal.pone.0041737.t004
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Use of herbs from the Fabaceae family was not associated with
significant liver fibrosis (adjPRR=1.6, 95% CI 0.26–10.3,
p=0.60).
Of 81 HIV-infected subjects with significant liver fibrosis, 4
(5%) reported herb use (see table 6). Among 387 HIV-infected
subjects without significant liver fibrosis, 4 (1%) reported herb use
(p=0.014). In the multivariable analysis of HIV-infected partic-
ipants adjusted for age, occupational fishing, positive HBsAg,
gender, heavy liquor use, ART, and CD4 nadir, the associations
between herb use and significant liver fibrosis were similar to
findings among all participants. Among HIV-infected participants
the use of any herb (adjPRR=2.3, 95% CI 1.0–5.0, p=0.044)
and the use of herbs from the Asteraceae family (adjPRR=5.0,
95% CI 1.7–14.7, p=0.004) were associated with increased liver
fibrosis.
Among all participants as well as HIV-infected participants,
herb use was not associated with increased hepatotoxicity. 8/41
(20%) of participants reporting herb use had ACTG grade 1–4
ALT elevations, compared to 216/961 (23%) who did not report
herb use (p=0.56). Among HIV-infected participants reporting
herb use, 6/33 (18%) had grade 1–4 ALT elevations, compared to
79/461 (17%) who did not report herb use (p=0.88).
Table 7 shows the proportion of participants who took
individual herbs in the Asteraceae, Lamiaceae, and Fabaceae
families who had significant liver fibrosis. 6/8 participants taking
herbs in the Asteraceae family had significant liver fibrosis. 4/6
subjects who used herbs in the Vernonia genus of the Asteraceae
family had significant liver fibrosis.
Discussion
This study indicates that traditional herbal medicine use may
contribute to liver disease in Uganda. Use of traditional herbal
medicines was independently associated with two to five fold
increases in significant liver fibrosis. Herbs from the Asteraceae
family were the most often used and showed the strongest
association with significant liver fibrosis: a five-fold increase in all
participants (p,0.001) and HIV-infected participants (p=0.004).
Six of eight participants who took herbs in the Asteraceae family
had significant liver fibrosis (see table 5). Many plants in the
Asteraceae and Fabaceae families contain pyrrolizidine alkaloids, a
known risk factor for veno-occlusive liver disease [7,17]. Although
none of the alkaloid-containing herbs used by participants in this
study have been confirmed to contain pyrrolizidine alkaloids,
ingestion of plants containing pyrrolizidine alkaloids caused
outbreaks of veno-occlusive liver disease in Jamaica, India, Egypt,
and South Africa [17,18]. No outbreaks of veno-occlusive liver
disease associated with pyrrolizidine alkaloids have been reported
to our knowledge in East Africa. Pyrrolizidine alkaloids are inert
until dehydrogenation by cytochrome P450 3A4 (CYP3A4) in the
liver [19], where reactive toxic pyrrolic and N-oxide metabolites
directly damage liver sinusoidal endothelial cells and hepatocytes
(zone III of the liver acinus) [20]. Pyrroles cause chromosomal
damage in a dose-dependent manner, resulting in an inflammatory
response that culminates in fibrin deposition [17,20,21].
Although plants in both the Asteraceae and Fabaceae families
ingested by study participants may contain pyrrolizidine alkaloids,
our data shows a strong association between significant liver
fibrosis and use of herbs in the Asteraceae family but not the
Fabaceae family. The literature about African traditional herbal
medicines is limited and does not explain why this difference might
exist. Traditional herbal medicine remedies used in Rakai and
throughout Uganda are often mixtures containing multiple herbs
[8,22]. It is possible that herbs in the Asteraceae family are taken
at high doses, or potentiate the toxicity of other herbs or
hepatotoxins.
Table 5. Association of herbs with significant liver fibrosis in
all participants.
Univariate Multivariate
Herb (n taking) PRR 95% CI P value adjPRR 95% CI P value
Any current herb use
(41)
2.2 1.3–3.6 0.003 2.2 1.3–3.5 0.002
Asteraceae (8) 5.5 3.6–8.4 ,0.001 5.0 2.9–8.7 ,0.001
Fabaceae (6) 1.2 0.19–7.1 0.86 1.6 0.26–10.3 0.60
Lamiaceae (5) 2.8 0.96.0–8.4 0.060 3.4 1.2–9.2 0.017
Unknown herb (21) 1.0 0.35–2.9 0.995 1.2 0.40–3.3 0.79
Multivariate model for all participants adjusts for: age, occupational fishing, HIV
infection, positive Hepatitis B surface antigen, gender, heavy liquor use
($1.25 L/week). Only participants with a valid TE scan (962/1000) were included
in the model. CI (Confidence Interval).
doi:10.1371/journal.pone.0041737.t005
Table 6. Association of herbs with significant liver fibrosis in
HIV-infected participants.
Univariate Multivariate
Herb (n taking) PRR 95% CI P value adjPRR 95% CI P value
Any current herb use
(8)
3.0 1.4–6.2 0.003 2.3 1.0–5.0 0.044
Asteraceae (2) 6.0 4.9–7.3 ,0.001 5.0 1.7–14.7 0.004
Unknown herb (5) 1.2 0.20–6.8 0.87 1.0 0.15–6.7 0.998
Multivariate model for HIV-infected participants adjusts for: age, occupational
fishing, positive Hepatitis B surface antigen, gender, heavy liquor use ($1.25 L/
week), ART, and CD4 nadir. Only participants with a valid TE scan (468/500)
were included in the model. CI (Confidence Interval).
doi:10.1371/journal.pone.0041737.t006
Table 7. Use of specific herbs and significant liver fibrosis.
Herb used
Proportion of participants taking
with significant liver fibrosis
Asteraceae Family 6/8
Vernonia amygdalina 2/4
Vernonia, species unknown 2/2
Microglossa densiflora 1/1
Aspilia Africana 1/1
Fabaceae Family 2/6
Pseudarthria hookeri 1/4
Indigofera congesta 1/2
Lamaceae Family 2/5 *
Ocimum gratissimum 1/3
Hoslundia opposita 1/3
*One participant took both Ocmum gratissimum and Hoslundia opposite.
Only participants with a valid TE scans are shown.
doi:10.1371/journal.pone.0041737.t007
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in the Asteraceae family. This particular herb is commonly used in
Africa is thought to have hepatoprotective properties [23].
However, animal studies show that at higher doses, this member
of the Asteracaae family may be hepatotoxic. In an in-vivo rat CCl4
liver injury model, low doses (250–500 mg/kg) of Vernonia
amygdalina were hepatoprotective, but a high dose (750 mg/kg)
caused increased hepatoxicity [24].
Herbs from the Lamiaceae family were associated with a 3.4
fold increase in significant liver fibrosis among all participants in
our study (p=0.017). Herbs in the Lamiaceae family have been
associated with hepatoxicity in an in-vivo rabbit model [25]. In
addition, Aloe, taken by two participants in our study, has been
linked in case reports to severe hepatitis [26]. However, data about
the potential hepatotoxicity of many herbs used by participants in
this study do not exist, or come from animal model studies only
that should be interpreted cautiously.
The risk of significant fibrosis associated with herb use was
similar in the overall and HIV- infected study populations. Data
on herb use was limited in the HIV-infected population, and plant
family specific analysis was only possible for the Asteraceae family.
Only two HIV- infected participants reported using herbs in the
Asteraceae family.
Despite the small number of HIV-infected participants in this
study who reported herb use, it is important to note that ART may
alter the toxicity profile of co-administered herbs. CYP3A4 is a
major pathway for metabolism of a wide range of chemically
distinct foreign compounds including phytochemicals and antiret-
roviral drugs [27]. Antiretroviral drugs of the non- nucleoside
reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)
classes are also inducers or inhibitors of CYP3A4 activity [28,29].
Therefore, these drugs have potential to influence phytochemical
toxification or detoxification pathways in the liver. For example,
commonly used NNRTI in initial ART regimens in Uganda
(efavirenz and nevirapine) are inducers of CYP3A4 and therefore
have potential to increase generation of toxic metabolites of
pyrrolizidine alkaloids [27,28]. Inhibitors of CYP3A4 may lead to
accumulation of phytochemicals or their metabolites in the liver
which may also result in toxicity.
Conversely, herbs may potentiate ART toxicities by influencing
antiretroviral drug disposition in the liver, kidney, and gut. Herbs
may affect NNRTI and PI metabolism by CPY3A4 and alter
activity of cellular drug transporters and glucuronidation pathways
[27]. Existing evidence from Africa about herb-ART interactions
is limited to two herb families commonly used in South Africa:
Hypoxis (African potato) and Sutherlandia, neither of which were
taken by participants in this study. Hypoxis causes a dose-
dependent inhibition of CYP3A4 up to 86% of the normal activity
of CYP3A4 and 50% reduction of the expression of P-
glycoprotein. Sutherlandia frutescens also causes a dose dependent
inhibition of CYP3A4 up to 96% of CYP3A4 activity [30]. One
participant in this study reported garlic use, which is known to
significantly reduce concentrations of a PI (saquinavir), most likely
by induction of CYP3A4 [31]. Since nevirapine and efavirenz are
also eliminated by CYP3A4, garlic may reduce plasma levels of
these drugs, but there are no clinical data on these interactions.
Limitations
This study had limitations. The study was cross-sectional and
only information about current herb use was available for analysis.
Only 4% of participants in this study reported using herbs,
compared to other studies in Uganda in which 60% of HIV-
infected persons reported concurrent use of ART and herbs [2].
Some misclassification of herb exposure could have occurred due
to a social desirability or reporting bias, especially among HIV-
infected persons on ART who are counseled to avoid herbs in the
communities around Rakai. Only 2% of HIV- infected partici-
pants reported herb use. While this lower number of HIV-infected
participants reporting herb use could represent effective counsel-
ing, the difference in herb use among those on ART and those not
on ART was not significant (1% vs. 2%, p=0.42). The small
number of participants reporting herb use limited many compar-
isons (e.g., herb-ART interactions) and suggests that our findings
should be interpreted cautiously.
An important limitation of this study is the potential for reverse
causality. Although the most frequently used families of herbs in
this study contain known hepatotoxins (see table 3), it is possible
that the association of fibrosis with herb use could represent
reverse causality, or persons with symptomatic liver disease being
more likely to use herbal medicines. According to consultations
with local traditional practitioners, some of the herbs in Asteraceae
and other families are sometimes prescribed for ‘‘fever with
jaundice’’. However, none of the study participants had been
previously diagnosed with liver disease within the formal medical
system or by traditional healers. Most herbs used in this study to
treat fever are usually taken for general fever (‘‘fever’’ or
‘‘malaria’’), not fever with jaundice (‘‘yellow fever’’).
Conclusions
More studies are needed to assess the impact of traditional
herbal medicines in sub-Saharan Africa. Phytochemical, pharma-
cokinetic and prospective clinical studies are needed to investigate
herb contents, benefits, side effects, direct toxicity, and herb-ART
interactions. Plants in the Asteraceae family reported in this study
should be prioritized for these investigations.
The risk of liver disease associated with herb use was similar in
the overall study population and among HIV-infected partici-
pants. Given the potential of at least additive risk of hepatotoxicity
with long term use of some antiretroviral drugs, as well as the
potential for herbs to alter the pharmacology of antiretroviral
drugs, it may be prudent to counsel HIV-infected persons against
herb use in sub-Africa until there is data about the safety of specific
herbs. Counseling about herb use should be part of routine health
counseling and counseling of HIV- infected persons in sub-Africa.
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